Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.64 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.62 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.62 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.62 |
| ▸ | RB1 | P06400 | 2/20 | 0.50 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.48 |
| ▸ | TOP1 | P11387 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3859034 | 1.00 | CHRNA7 (0.64) | CHRNA7ADRA1AADRA1DADRA1BRB1 | |
| Desbromoarborescidine A SCHEMBL5269957 | 0.99 | CHRNA7 (0.66) | CHRNA7ADRA1AADRA1DADRA1BRB1 | |
| Desbromoarborescidine A SCHEMBL30363173 | 0.99 | CHRNA7 (0.66) | CHRNA7ADRA1AADRA1DADRA1BRB1 | |
| Desbromoarborescidine A SCHEMBL29002756 | 0.99 | CHRNA7 (0.66) | CHRNA7ADRA1AADRA1DADRA1BRB1 | |
| Desbromoarborescidine A SCHEMBL31662855 | 0.99 | CHRNA7 (0.66) | CHRNA7ADRA1AADRA1DADRA1BRB1 | |
| SCHEMBL30363084 | 0.94 | CHRNA7 (0.67) | CHRNA7ADRA1AADRA1DADRA1BBRD3 | |
| SCHEMBL2887057 | 0.94 | CHRNA7 (0.67) | CHRNA7ADRA1AADRA1DADRA1BBRD3 | |
| SCHEMBL30363160 | 0.94 | CHRNA7 (0.67) | CHRNA7ADRA1AADRA1DADRA1BBRD3 | |
| Desbromoarborescidine A SCHEMBL30621266 | 0.91 | CHRNA7 (0.58) | CHRNA7ADRA1AADRA1DADRA1BRB1 | |
| SCHEMBL24240060 | 0.81 | CHRNA7 (0.61) | CHRNA7ADRA1AADRA1DADRA1BADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220218695-A1 | COMBINATION OF AN ALPHA2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2022-07-14 | — | — | US | disclosed |
| EP-3965762-A1 | COMBINATION OF AN ?2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA | Bayer Aktiengesellschaft (DE) | 2022-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220218695-A1 | COMBINATION OF AN ALPHA2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA | ADRA2C, ADRB2, CHRNA1 | CHRNA7 18/4885ADRA1A 12/4885ADRA1D 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.